Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...

Over the weekend, Novo unveiled data from the phase 3 Real8 study, which found that the company’s once-weekly human growth hormone analogue Sogroya was largely on par with its daily predecessor ...

Asda customers have recycled over 3 million coffee pods since the start of 2025 after the supermarket launched a new coffee pod recycling service. In January, Asda partnered with Podback to roll out a ...

Weight loss leader Novo Nordisk has had a poor performance at ... The first big price fall came after the company released its phase 3 trial results in late December last year.

After testing the Eight Sleep's latest, here’s I think you should just stick with the Pod 3 and save $354. Caroline Igo (she/her/hers) is a wellness editor and holds Sleep Science Coach and ...

Novo Nordisk has announced headline results from a late-stage study of its obesity candidate CagriSema in adults with type 2 diabetes (T2D). The phase 3 REDEFINE 2 trial has been evaluating ...

Novo Nordisk on Friday revealed disappointing ... CagriSema is still the best weight loss reported in a Phase 3 trial,” he said. Investors noted that the two other patient groups in the trial ...